Alberto Bardelli

72.6k citations

264 papers · 32.1k indexed · 18 hit papers · h-index 80

Impact in

Cancer Research top 0.02%
- Cancer Genomics and Diagnostics
Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis

Papers in

Cancer Research 102
- Cancer Genomics and Diagnostics 88
Oncology 143
- Colorectal Cancer Treatments and Studies 90

Co-authors: Salvatore Siena Federica Di Nicolantonio Luis A. Díaz Andrea Sartore‐Bianchi Silvia Marsoni Kenneth W. Kinzler Bert Vogelstein Victor E. Velculescu
Journals: Journal of Clinical Oncology (20 papers)Annals of Oncology (20 papers)Cancer Research (16 papers)Clinical Cancer Research (11 papers)Molecular Oncology (10 papers)
Partner nations: Italy United States Spain

In The Last Decade

Alberto Bardelli

256 papers receiving 31.5k citations

Hit Papers

15 papers align trajectories log scale

High-dose vitamin C enhances cancer immunotherapy 2020 · 199 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Science Translational Medicine
2018 Molecular Oncology
2017 Nature Reviews Clinical Oncology
2014 Journal of Clinical Oncology
2014 Cancer Discovery
2013 Nature Reviews Clinical Oncology
2012 Nature
2010 Journal of Clinical Oncology
2010 JAMA
2009 Cancer Research
2008 Journal of Clinical Oncology
2007 Cancer Research
2005 The Lancet Oncology
2004 Science
2002 Nature
2001 Science
1994 Cell
1991 The EMBO Journal

Peers

Countries citing papers authored by Alberto Bardelli

Since Specialization

Citations

This map shows the geographic impact of Alberto Bardelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Bardelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Bardelli more than expected).

Fields of papers citing papers by Alberto Bardelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Bardelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Bardelli. The network helps show where Alberto Bardelli may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alberto Bardelli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alberto Bardelli Line = papers co-authored together Alberto Bardelli links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Early-onset cancers: Biological bases and clinical implications Cell Reports Medicine ·Gianluca Mauri, Giorgio Patelli, Andrea Sartore‐Bianchi, Sergio Abrignani, Beatrice Bodega, Silvia Marsoni, Vincenzo Costanzo, Angela Bachi, Salvatore Siena, Alberto Bardelli	2024	18
2	LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients Annals of Oncology ·Sara Lonardi, Filippo Pietrantonio, Istiaque Muhammad Khan, 練愷恩, Gomes de Oliveira Luz, Maria Giulia Zampino, Hanako Aoki, Qingguo Zhu, Mario Mandalà, Stefano Tamberi, Durno Murray, Susana Muñoz, Luca Lazzari, Paolo Luraghi, Valter Torri, Andrés Cervantes, Alberto Bardelli, Josep Tabernero, Salvatore Siena, Silvia Marsoni	2023	32
3	Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT) Cell Death and Disease ·왕진중, Giulia Dell’Omo, Elena Grassi, Jean Falgarone, Simonetta M. Leto, F. Novce, Annalisa Lorenzato, Sabrina Arena, Andrea Bertotti, Livio Trusolino, Alberto Bardelli, Fabrizio d’Adda di Fagagna	2023	3
4	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations Clinical Cancer Research ·Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman	2019	115
5	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients Clinical Cancer Research ·Carmine Carbone, Geny Piro, Francesca Simionato, Francesca Ligorio, Chiara Cremolini, Fotios Loupakis, Greta Alì, Daniele Rossini, Valeria Merz, Raffaela Santoro, Camilla Zecchetto, Marco Zanotto, Federica Di Nicolantonio, Alberto Bardelli, Gabriella Fontanini, Giampaolo Tortora, Davide Melisi	2017	41
6	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF -Mutated Colorectal Cancer Cancer Discovery ·Filippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, Emanuele Valtorta, Rosa Berenato, Ludovic Barault, Marta Caporale, Adele Busico, Federica Morano, Ambra V. Gualeni, Alessandra Alessi, Giulia Siravegna, Federica Perrone, Maria Di Bartolomeo, Alberto Bardelli, Filippo de Braud, Federica Di Nicolantonio	2016	78
7	Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature Cancer Research ·M. G. Ostronov, Federica Maione, Mélissande Cossutta, Gilles Carpentier, David Stuedell, Johan Van Langen, 庆郭, Damien Destouches, Ksenya Shchors, Yash Parikh, Fabien Mongélard, Simona Lamba, Alberto Bardelli, Philippe Bouvet, Anne Couvelard, José Courty, Enrico Giraudo, Ilaria Cascone	2016	100
8	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer Cancer Discovery ·Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong, Ryan B. Corcoran	2015	138
9	Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer Clinical Cancer Research ·Θεοδώρα Κάτσιλα, О.Я. Сулейменова, Josep Gregori, Teresa Macarulla, Laura Villarreal, Alberto Bardelli, Chris Torrance, Élena Elez, Josep Tabernero, Josep Villanueva	2014	22
10	TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells Clinical Cancer Research ·Sebastijan Hobor, Beth O. Van Emburgh, Emily Crowley, Sandra Misale, Federica Di Nicolantonio, Alberto Bardelli	2014	84
11	BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors Molecular Cancer Therapeutics ·Davide Zecchin, Valentina Boscaro, Enzo Médico, Ludovic Barault, Miriam Martini, Sabrina Arena, Carlotta Cancelliere, Alice Bartolini, Emily Crowley, Alberto Bardelli, V. Dubenskyy, Federica Di Nicolantonio	2013	16
12	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET Clinical Cancer Research ·Cristina Basilico, Selma Pennacchietti, Elisa Vigna, Cristina Chiriaco, Sabrina Arena, Alberto Bardelli, Donatella Valdembri, Guido Serini, Paolo Michieli	2013	138
13	Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis Cancer Research ·Miriam Martini, Mariangela Russo, Simona Lamba, Elisa Vitiello, Emily Crowley, Francesco Sassi, Davide Romanelli, Milo Frattini, Antonio Marchetti, Alberto Bardelli	2013	16
14	Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas Clinical Cancer Research ·Giorgia Migliardi, Francesco Sassi, Davide Torti, Francesco Galimi, Eugenia R. Zanella, Michela Buscarino, Dario Ribero, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Mauro Risio, Lorenzo Capussotti, Silvia Marsoni, Federica Di Nicolantonio, Alberto Bardelli, Paolo M. Comoglio, Livio Trusolino, Andrea Bertotti	2012	147
15	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K - Ras Mutant Colorectal and Pancreatic Cancers Clinical Cancer Research ·Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Federica Di Nicolantonio, Aldo Scarpa, Alberto Bardelli, Giampaolo Tortora	2011	44
16	PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies Cancer Research ·Andrea Sartore‐Bianchi, Miriam Martini, Francesca Molinari, Silvio Veronese, Michele Nichelatti, Salvatore Artale, Federica Di Nicolantonio, Piercarlo Saletti, Sara De Dosso, Luca Mazzucchelli, Milo Frattini, Salvatore Siena, Alberto Bardelli Hit paper breakdown →	2009	601
17	Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma Cancer Research ·Asha Balakrishnan, Fonnet E. Bleeker, Simona Lamba, Monica Rodolfo, Maria Daniotti, Aldo Scarpa, Angela A. van Tilborg, Sieger Leenstra, Carlo Zanon, Alberto Bardelli	2007	128
18	Knock-in of Oncogenic Kras Does Not Transform Mouse Somatic Cells But Triggers a Transcriptional Response that Classifies Human Cancers Cancer Research ·Sabrina Arena, Claudio Isella, Miriam Martini, Ario de Marco, Enzo Médico, Alberto Bardelli	2007	25
19	High Frequency of Mutations of the PIK3CA Gene in Human Cancers Science ·Yardena Samuels, Zhenghe Wang, Alberto Bardelli, Natalie Silliman, Janine Ptak, Steve Szabo, Hai Yan, Adi F. Gazdar, Steven M. Powell, Gregory J. Riggins, James K. V. Willson, Sanford D. Markowitz, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu Hit paper breakdown →	2004	2708
20	Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers Science ·Zhenghe Wang, Dong Shen, D. Williams Parsons, Alberto Bardelli, Jason A. Sager, Steve Szabo, Janine Ptak, Natalie Silliman, Brock A. Peters, Michiel S. van der Heijden, Giovanni Parmigiani, Hai Yan, Tian‐Li Wang, Greg Riggins, Steven M. Powell, James K. V. Willson, Sanford D. Markowitz, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu	2004	412

About Alberto Bardelli

Alberto Bardelli is a scholar working on Cancer Research, Oncology, Hepatology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 264 papers that have together received 32.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (90 papers), Cancer Genomics and Diagnostics (88 papers), Genetic factors in colorectal cancer (55 papers), Lung Cancer Treatments and Mutations (50 papers), PI3K/AKT/mTOR signaling in cancer (35 papers), Liver physiology and pathology (31 papers), Gastric Cancer Management and Outcomes (20 papers) and Protein Kinase Regulation and GTPase Signaling (17 papers). The work is most often cited by research in Cancer Research (10.3k citations), Oncology (15.4k citations), Hepatology (4.0k citations), Pathology and Forensic Medicine (7.2k citations) and Pulmonary and Respiratory Medicine (7.9k citations). Alberto Bardelli has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Salvatore Siena, Federica Di Nicolantonio, Luis A. Díaz, Andrea Sartore‐Bianchi, Silvia Marsoni, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Paolo M. Comoglio and Giulia Siravegna. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and Molecular Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact